e-learning
resources
Madrid 2019
Sunday, 29.09.2019
Paediatric respiratory infections around the world: Tuberculosis, pneumonia and others
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
NT pro-NB as a marker of the pneumonia severity in children.
J. Lange (Warsaw, Poland), H. Marczak (Warsaw, Poland), K. Krenke (Warsaw, Poland), J. Peradzynska (Warsaw, Poland)
Source:
International Congress 2019 – Paediatric respiratory infections around the world: Tuberculosis, pneumonia and others
Session:
Paediatric respiratory infections around the world: Tuberculosis, pneumonia and others
Session type:
Thematic Poster
Number:
994
Disease area:
Paediatric lung diseases, Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Lange (Warsaw, Poland), H. Marczak (Warsaw, Poland), K. Krenke (Warsaw, Poland), J. Peradzynska (Warsaw, Poland). NT pro-NB as a marker of the pneumonia severity in children.. 994
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Prevalence of hyponatremia (HN) in children with community acquired pneumonia (CAP) and its relation to disease severity, outcomes
Source: Virtual Congress 2021 – Acute paediatric respiratory infections
Year: 2021
Correlation between pneumonia severity index and mortality within 30 days after the diagnosis of community-acquired pneumonia in elderly subjects
Source: Eur Respir J 2006; 28: Suppl. 50, 741s
Year: 2006
The pneumonia severity index (PSI) do not underestimate the severity of community-acquired pneumonia (CAP) in young patients: results from the CAPO international study
Source: Annual Congress 2008 - Factors related to outcome of community-acquired pneumonia
Year: 2008
Is severity index enough to assess hospital admission of community-acquired pneumonia (CAP) patients?
Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia
Year: 2006
Lactate is an independent marker of severity in hospitalised patients with community-acquired pneumonia
Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia
Year: 2011
Definition of severity and the reasons for hospitalization (RH) in patients with community-acquired pneumonia (CAP)
Source: Eur Respir J 2005; 26: Suppl. 49, 641s
Year: 2005
I-ROAD could be efficient in predicting severity of community acquired pneumonia (CAP) or healthcare-associated-pneumonia(HCAP)
Source: Annual Congress 2010 - Healthcare-associated pneumonia: ventilator-associated pneumonia and pneumonia in hospitalised patients
Year: 2010
Management-based risk prediction in community-acquired pneumonia by scores and biomarkers
Source: Eur Respir J 2013; 41: 974-984
Year: 2013
C-reactive protein as severity biomarker in patients with community-acquired pneumonia (CAP)
Source: Eur Respir J 2005; 26: Suppl. 49, 545s
Year: 2005
Biomarkers and community acquired pneumonia (CAP) severity
Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia
Year: 2011
Biomarkers and community acquired pneumonia (CAP) severity
Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity
Year: 2010
Community-acquired pneumonia (CAP) in alcoholic patients (AL): differences in aetiology and severity
Source: Eur Respir J 2002; 20: Suppl. 38, 560s
Year: 2002
Systemic cytokine levels in community-acquired pneumonia and their association with disease severity
Source: Eur Respir J 2002; 20: 990-995
Year: 2002
Which is the most effective inflammatory marker in the diagnosis, severity and treatment follow-up of patients with pneumonia?
Source: International Congress 2019 – Prognosis in bacterial and viral pneumonia
Year: 2019
Use of pneumonia severity index in Spain to decide hospitalization among patients with community-acquired pneumonia (CAP). (Nacar Study)
Source: Eur Respir J 2005; 26: Suppl. 49, 637s
Year: 2005
Characterization of community acquired pneumonia (CAP) with severe sepsis at diagnosis
Source: Annual Congress 2012 - Epidemiology: risk factors and prognosis in respiratory infections
Year: 2012
Procalcitonin and C reactive protein as markers of treatment failure in community-acquired pneumonia
Source: Annual Congress 2006 - Inflammation markers in community-acquired pneumonia
Year: 2006
Defining prognostic factors in the elderly with community acquired pneumonia: a case controlled study of patients aged >=75 yrs
Source: Eur Respir J 2001; 17: 200-205
Year: 2001
Physicians should not use the pneumonia severity index (PSI) or CRB-65 in deciding the need for hospitalization in cancer patients with community-acquired pneumonia (CAP)
Source: Eur Respir J 2007; 30: Suppl. 51, 41s
Year: 2007
Initial and persistent inflammatory response in treatment failure in community-acquired pneumonia
Source: Annual Congress 2007 - Prognostic laboratory tests in community-acquired pneumonia
Year: 2007
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept